MedTrace Logo

Air Pollution and Allergens - Attenuation of Health Effects Particle Reduction

NCT02017431 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2017-09-29

No results posted yet for this study

Summary

The study probes the effects of combined exposures to diesel exhaust and allergens on lung function and on the immune system, specifically focusing on the ability of a particle depletion technique to attenuate effects we and others have seen previously. Individuals are exposed to either filtered air (FA), carefully controlled levels of diesel exhaust (DE) or particle-depleted diesel exhaust (PDDE) in our exposure chamber, after which the investigators will administer an inhaled allergen challenge. 48h later, a procedure called bronchoscopy is used to collect samples from the lungs. After 1 month, the entire procedure is to be repeated with one of the alternate exposures. This will be repeated 4 times (4 exposures; 2 filtered air, 1 diesel exhaust, 1 particle-depleted diesel exhaust)

Conditions

Interventions

OTHER

Allergen

Subject specific allergen is inhaled on day 1 of the triad

OTHER

Saline

Saline is inhaled on day 1 of the triad

OTHER

Particle depleted diesel exhaust

High-efficiency particulate filtration of diesel exhaust

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Christopher Carlsten, MD, MPH · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2017-04-30
Completion
2017-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02017431 on ClinicalTrials.gov